Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CDC25A | P30304 | 2/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 9/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228382 | 1.00 | CYP19A1 (0.43) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL20243735 | 0.85 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL12464968 | 0.82 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL9010441 | 0.82 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL13852396 | 0.82 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL13669231 | 0.82 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL18193607 | 0.79 | CDC25A (0.44) | CYP19A1CDC25ACDC25BVDR | |
| SCHEMBL9925372 | 0.79 | CDC25A (0.44) | CYP19A1CDC25ACDC25BVDR | |
| SCHEMBL13641549 | 0.77 | CDC25A (0.53) | CDC25ACDC25BVDRMEN1PGR | |
| SCHEMBL4787102 | 0.77 | CDC25A (0.46) | CYP19A1CDC25ACDC25BVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | MCGILL UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | MCGILL UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | VDR, HDAC3, HDAC4 | CYP19A1 574/4885CDC25A 4255/4885CDC25B 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.